Cardinal Health, Inc. (CAH)

Cardinal Health is trading near the top of its 52-week range after a run of analyst reaffirmations and a strong fiscal first-quarter report. The stock closed at $276.79 and sits 91% of the way up its 52-week range, with the 52-week high at $286.29. Shares are up 16.51% over the past month and 51.62% over six months, and the stock is above its 50-day and 200-day moving averages ($242.12 and $224.10). The question for investors is whether earnings growth can keep pace with a share price that already prices in much of the recovery. CleaRank rates the stock Buy with a score of 77 out of 100.

Cardinal Health has beaten EPS estimates in all seven of the recent reports on the earnings record. The November 5, 2026 report delivered adjusted EPS of $3.26 against an estimate of $2.94, a beat of 10.88%, and the stock rose 1.46% in the first session afterward. The August 11, 2026 report beat by 7.44%, but the shares fell 2.54% in the next session. Across the seven reports, three beats were followed by a lower share price, so a beat has not reliably translated into a gain on the day.

Margins are thin: the net profit margin is 0.70% and the operating margin is 1.34%. The company's health score on CleaRank is 3 out of 5, reflecting solid execution on earnings but a slower top line and narrow profitability.

The trailing P/E of 35.49 sits 11.3% above the Healthcare sector median of 31.9, which is broadly in line with peers. The price-to-sales ratio of 0.25 is far below the sector median of 3.4, reflecting how low margins are relative to sales. Of 17 analysts, 14 rate the stock buy or strong buy, three hold it and none sell it. Morgan Stanley kept its Overweight rating on October 30, 2026, and RBC Capital and Evercore ISI both kept Outperform ratings on November 6, 2026.

Insiders sold $112.5M of stock over the last 18 months across 19 sales and made no open-market purchases. Such sales are often planned in advance or made to cover tax on vesting shares, so they carry less weight than purchases would.

The base case is that Cardinal Health holds its gains while earnings estimates keep rising. Analysts expect EPS of $13.00 for this fiscal year, up 18.8%, and $14.29 for next fiscal year, up 9.9%. Those forecasts support the current valuation only if revenue growth picks up from the 5.50% reported in the latest quarter, which trails the sector median of 8.1%. The analysts' median 12-month target is $290.00, with a range of $260.00 to $330.00. The case would weaken if the price falls back through the 20-day EMA and 50-day SMA, or if the next quarterly report misses estimates after a run of seven straight beats. Because the stock is already overbought on RSI, a pullback is more likely to come from profit-taking than from a change in the fundamental picture.

Support sits at $256.78, the 20-day exponential moving average, which is the nearest level below the price. Below it, the 50-day simple moving average at $242.12 is the next floor, followed by the 200-day simple moving average at $224.10. The 52-week low at $180.45 is the deepest reference point. On the upside, the 52-week high at $286.29 is the first resistance; a close above it would mark a new 52-week high for the stock.